IBD98-M
Inflammatory bowel disease
PreclinicalActive
Key Facts
About Holy Stone Healthcare
Taiwan biotech leveraging hyaluronic‑acid biopolymers for targeted brain, eye, and tumor drug delivery.
View full company profileTherapeutic Areas
Other Inflammatory bowel disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Turq-101 | Turquoise Biotechnologies | Preclinical |
| GS-4875 | Gilead | Phase 2 |
| Function-based Consortium for IBD | PharmaBiome | Pre-clinical |
| Galapagos Collaboration | Scipher Medicine | Discovery/Pre-clinical |
| IBD Subclassification | Bio-Me | Research |
| Anti-iRhom2 antibodies | SciRhom | Pre-clinical |
| IBD Multi-omics Dataset | Ovation.io | Commercial |
| Noa‑001 | Noa Therapeutics | Preclinical |
| Inflectra | EMS | Phase 3 |
| IW-601 | ImmuneWalk Therapeutics | Preclinical |
| TRWR‑IBD | Taiwan Resonant Waves Research | Preclinical |
| Zymfentra™ | Celltrion | Marketed |